5-Amino-1MQ has zero published human trials. The mechanism is real and genuinely interesting. The results circulating for it come from mice, and from a mouse study that also changed the diet.
5-Amino-1MQ is not a peptide. It is a small molecule that blocks an enzyme called NNMT, sold by peptide vendors. The mechanism is real. The animal work is real too: treated mice lost about 35% of one fat depot. Human trials number zero. And the headline rodent study also put the mice on a low-fat diet, so the diet sits inside the result. For scale, tirzepatide and semaglutide reached 20–25% in Phase III.
What the strongest study actually did
The finding driving this entire category is a 2022 mouse study. It combined NNMT inhibition with a reduced-calorie, low-fat diet and reported a substantial drop in adipose tissue.
Read the design again: the diet was part of the intervention. A study that changes two things and reports one result cannot tell you how much either contributed, and diet alone produces fat loss in mice reliably.
That is not a criticism of the study, which was asking a legitimate question about combination effects. It is a caution about how the result is being quoted. The 5-Amino-1MQ fat-loss research covers what each paper measured.
The mechanism is the good part
NNMT is a genuinely interesting target and the case for it does not depend on marketing.
The enzyme methylates nicotinamide, consuming methyl donors and shunting nicotinamide away from NAD+ salvage. Knock it down in mice on a high-fat diet and they resist diet-induced obesity. That knockdown result is the foundational paper in the field and it holds up.
Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity.
Kraus et al., Nature, 2014Treatment of DIO mice with the NNMT inhibitor resulted in a substantial ~35% decrease in the mass and size of the EWAT.
Neelakantan et al., Biochemical Pharmacology, 2018A ~35% drop in epididymal white adipose tissue is a large effect, and it is the number the marketing is really drawing on. It was measured in diet-induced-obese mice given 20 mg/kg per injection over 11 days.
Selective, membrane-permeable small-molecule inhibitors followed, which is where 5-Amino-1MQ comes from. It is a research tool compound and it does what it says on the enzyme.
None of that is a human result, and the distance between a validated target and a working drug is where most drug development fails. See the NNMT mechanism.
What it is competing against
Fat-loss photographs have an unusually clear benchmark now, because the compounds that work have been measured precisely.
| Compound | Human evidence | Measured result |
|---|---|---|
| Tirzepatide | Phase III | 22.5% body weight |
| Semaglutide | Phase III | 14.9% body weight |
| 5-Amino-1MQ | None | — |
The comparison is not meant to be unkind to the compound. It is the context a reader needs, because a photograph does not come labeled with which column it belongs to.
5-Amino-1MQ
The NNMT inhibitor discussed here, supplied as a research compound with a batch-matched certificate of analysis.
It is not a peptide, which matters for what you are buying
5-Amino-1MQ is a quinolinium small molecule. It lives in peptide catalogs and peptide conversations, but it is a different kind of substance, and two practical consequences follow.
- The certificate reads differently. Purity by HPLC and identity by mass spec still apply, but there is no amino-acid sequence to confirm, so sequence verification is not available as a check.
- It is usually sold as capsules. Oral is the route the tool-compound literature used, which at least matches, unlike most of this market.
- Handling differs. It is not a lyophilized peptide and does not follow the same reconstitution or storage logic — see peptide storage temperature.
Is NAD+ a peptide covers the same category confusion for a neighboring compound.
How to read a 5-Amino-1MQ before-and-after
With no human data at all, the checks are simpler than usual and the answer is more definite.
- Any human study cited? There are none. A page citing one is citing a mouse study or something unrelated.
- Was a diet involved? In the headline animal result, yes, and in almost every personal result too.
- What is the claimed magnitude? Changes on the scale of GLP-1 results, from a compound with no trials, are describing something else.
The compound is early, not fake. Those are different, and the honest description is a validated target with a real tool compound and no clinical evidence. Best peptides for weight loss puts it against the alternatives.
5-Amino-1MQ
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- Zero human trials have been published. Not a failed one, not a small one. None.
- The headline rodent result paired the compound with a low-fat, reduced-calorie diet, so the diet is inside the finding.
- The target is validated: NNMT knockdown protects mice against diet-induced obesity, in a 2014 Nature paper.
- It is a small molecule, not a peptide, so sequence verification is not available as a certificate check.
- For scale, tirzepatide and semaglutide produced 20–25% body-weight reduction in Phase III trials.
What we're watching
The single thing that would change this page is a first-in-human study, and the compound is far enough along as a tool that one is technically possible. Watch for a registered Phase I: safety and pharmacokinetics in healthy volunteers would tell you more than another decade of rodent work. Watch also for any rodent study that separates the compound from the diet, since the headline result currently bundles them and that bundling is doing more work than the citations admit.
Frequently asked questions
Are there real 5-Amino-1MQ before and after results?
No published ones. Zero human trials of any kind have been run on this compound, so there is no measured result to report. Photographs in circulation have no study behind them.
What is the strongest evidence for 5-Amino-1MQ?
A 2022 mouse study combining NNMT inhibition with a reduced-calorie, low-fat diet, which reported a substantial drop in adipose tissue. The diet was part of the intervention, so the compound's own contribution is not separable from that result.
Is 5-Amino-1MQ a peptide?
No. It is a quinolinium small molecule that inhibits the enzyme NNMT. It is sold by peptide vendors and discussed alongside peptides, but it is a different class of substance with no amino-acid sequence to verify.
How long does 5-Amino-1MQ take to work?
Unknown in humans, because no human study has measured anything. Any timeline in circulation is extrapolated from rodent work or from personal reports.
Is the NNMT mechanism real?
Yes. NNMT knockdown protects mice against diet-induced obesity, published in Nature in 2014, and selective membrane-permeable inhibitors followed. A validated target is a genuine reason for interest and is not the same as a clinical result.
References
- Dimet-Wiley, A., Wu, Q., Wiley, J. T., et al. (2022). Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Scientific Reports, 12(1), 484. https://doi.org/10.1038/s41598-021-03670-5
- Neelakantan, H., Brightwell, C. R., Graber, T. G., et al. (2019). Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical Pharmacology, 163, 481–492. https://doi.org/10.1016/j.bcp.2019.02.008
- Kraus, D., Yang, Q., Kong, D., et al. (2014). Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature, 508(7495), 258–262. https://doi.org/10.1038/nature13198
- Neelakantan, H., Vance, V., Wetzel, M. D., et al. (2018). Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high-fat diet-induced obesity in mice. Biochemical Pharmacology, 147, 141–152. https://doi.org/10.1016/j.bcp.2017.11.007
- Pissios, P. (2017). Nicotinamide N-methyltransferase: More than a vitamin B3 clearance enzyme. Trends in Endocrinology & Metabolism, 28(5), 340–353. https://doi.org/10.1016/j.tem.2017.02.004
- Yang, M., Wang, B., Hou, W., et al. (2024). NAD metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer. Journal for ImmunoTherapy of Cancer, 12(7), e009281. https://doi.org/10.1136/jitc-2024-009281